TSXV: DVA
TORONTO, April 18, 2018 /CNW/ - Delivra Corp. ("Delivra",
or "the Company") today announced the publication of positive data
from a pre-clinical study demonstrating the safety and greater
bioavailability of transdermal berberine and dihydroberberine (DHB)
for the prevention and treatment of cardiovascular disease related
to high cholesterol and triglyceride levels. These results were
published in the respected peer-reviewed scientific journal, PLOS
ONE, under the title, "Comparative Pharmacokinetics and Safety
Assessment of Transdermal Berberine and Dihydroberberine". The
article may be found at the following link:
https://doi.org/10.1371/journal.pone.0194979.
"This promising data supports Delivra's research and proprietary
development of topical berberine and DHB's effectiveness to
successfully reduce cholesterol and triglyceride levels. In certain
cases, this treatment may provide a natural alternative to the use
of statin drugs. A Delivra-berberine therapy could avoid the side
effects associated with statin drugs, including, muscle pain, liver
damage, upset stomach and a range of neurological issues. This
achievement represents a platform in reducing cholesterol,
triglycerides and other forms of cardiovascular disease and
demonstrates our proprietary transdermal delivery system has the
capability to effectively deliver a broad range of
pharmaceutical and natural molecules to continue to build our
pharmaceutical portfolio," said Dr. Joseph
Gabriele, CEO of Delivra.
Transdermal DHB from Delivra overcomes challenges of oral
medications, showing 7-times higher concentration levels in the
blood than oral, with no gastrointestinal side effects.
Furthermore, in a previous study, transdermal DHB proved more
effective than oral in reducing cholesterol and triglycerides in a
model of metabolic disease.
Delivra has a PCT patent application to protect its unique
berberine formulations. This publication, authored by Beth Buchanan, Qingfang
Meng, Mathieu-Marc Poulin,
Jonathan Zuccolo, Chike Azike, Joseph
Gabriele, and David
Baranowski, was partially supported by Innovation PEI
through a post-doctoral award, by the Atlantic Canada Opportunities
Agency through equipment funding, and by the National Research Council - Industrial Research
Assistance Program.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin, in a
targeted manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivReliefTM brand, for
conditions such as joint and muscle pain, nerve pain, varicose
veins, wound healing, and under the LivSportTM brand for
sports performance. LivReliefTM products are available
in pharmacies, grocery chains, and independent health food stores
across Canada, including, but not
limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall,
Pharmasave, London Drugs, and on-line at www.livrelief.com. In
parallel with its consumer products business, Delivra also has a
mandate to license its patent-pending, proprietary transdermal
delivery technology platform to pharmaceutical companies globally,
for the repurposing of pharmaceutical molecules transdermally to
treat a broad range of conditions, along with licensing its
over-the-counter products globally. Delivra is headquartered in
Hamilton, Ontario and has a
research and development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at
www.delivracorp.com and www.livrelief.com.
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's revenues and financial
performance; the Company's drug research and development plans; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Delivra to differ materially from those
anticipated or implied in such forward-looking statements. The
Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no
assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein,
management has assumed that business and economic conditions
affecting Delivra will continue substantially in the ordinary
course and will be favourable to Delivra; that the Company will
continue to complete orders with existing customers and control
product pricing and expenses that clinical testing results will
justify commercialization of the Company's drug candidates; that
Delivra will be able to obtain all requisite regulatory approvals
to commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include: the
ability of the Company to maintain existing product sales with
current customers at existing product pricing and expenses;
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the ability of the Company to generate sales and
profits; the Company's ability to raise additional capital if and
when necessary; intellectual property disputes; increased
competition from pharmaceutical and biotechnology companies;
changes in equity markets, inflation, and changes in exchange
rates; and other factors as described in detail in Delivra's public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given
these risks and uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
Except as required by law, Delivra disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp